Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (December 2022)
38 slides from Syngene International's investor presentation, December 2022
Slide 1: Investor Presentation December 2022
Investor Presentation December 2022
Slide 2: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 3: Contents
Contents 1 Operating Highlights 2 Syngene – Putting Science to Work 3 Syngene strengths 4 Financials 5 Shareholding and Share Information Appendix Putting Science to Work 3
Slide 4: Operating Highlights
Ml Operating Highlights Syngene
Slide 5: Q3 FY23 performance
Q3 FY23 performance Operating Highlights Q3 Financial Highlights • Positive performances in all divisions • Sustained growth in Research divisions - Discovery Services and the Dedicated Centers • Development Services growth was primarily driven by repeat orders from existing clients and a growing nu
Slide 6: Upgraded FY23 full year guidance maintained
Upgraded FY23 full year guidance maintained FY23 Guidance Revised FY23 Guidance FY23 Guidance Parameter (April 2022) (July 2022) (December 22) Mid-teen High- teen High- teen Revenue from operations growth growth growth EBITDA margin EBITDA margin EBITDA margin EBITDA Margin around 30% around 30% aro
Slide 7: Syngene – Putting Science to Work
2 Syngene – Putting Science to Work
Slide 8: Partner in innovation: #Puttingsciencetowork
Partner in innovation: #Puttingsciencetowork Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated Sector expertise include Our team includes more Established track record in solutions across pharmaceuticals, biotech,
Slide 9: Key facts and figures
Key facts and figures 400+ 15 400+ World class active clients collaborations patents infrastructure with top 20 pharmaceutical held with clients of 2 Mn sq. ft. qualified to companies meet international standards Rs. 39,435 Mn Rs. 26,570 Mn Rs. 4,211 Mn ~6,000 headcount (US$526Mn*) (US$354Mn*) (US$5
Slide 10: International accreditations
International accreditations • USFDA,OHSAS 18001 • GLP, cGMP, AAALAC & CPCSEA Certified facilities • CAP accreditation, ISO/IEC 27001:2013 accreditation • EMA and PMDA approved, AAALAC accredited facility • The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:201
Slide 11: Our experience spans multiple industry segments and partnerships with global leaders
Our experience spans multiple industry segments and partnerships with global leaders across the world Large & Emerging Animal Consumer mid-sized Universities Agrochem biopharma health products biopharma Putting Science to Work 11
Slide 12: Our journey so far
Our journey so far 2019 – 2022 Continued investments and Globalization and strategic collaboration • Expanded into formulations development growth • Contract with Endo Pharmaceuticals to develop novel anti cancer • Expanded collaboration with BMS, biological therapeutic molecules Amgen and Zoetis •
Slide 13: Our broad capabilities, spanning the value chain
Our broad capabilities, spanning the value chain, facilitates integration and captures additional benefits for clients Research business Development and Manufacturing business Discovery Services Dedicated R&D Centers Development Services Manufacturing Services Flexible Platform with capability Ring-
Slide 14: A 'one-stop-shop' for discovery research, development and manufacturing services
A 'one-stop-shop' for discovery research, development and manufacturing services (small and large molecules) Discovery Development Manufacturing Small Drug Substance Chemistry Molecules Large Development Clinical Supplies Molecules Drug Product Development Biology Integrated Drug Substance – Drug Pr
Slide 15: Flexible collaboration models
Flexible collaboration models 1 2 3 4 5 6 Dedicated R&D centers Full time equivalent (FTE) Fee for service Productivity-based model Risk-reward Delivery-based contract for CDMO business • Dedicated scientific • Pre-defined numbers • Client contracts for • Resources and services • Relationship spans
Slide 16: Our state-of-the-art infrastructure
Our state-of-the-art infrastructure Bangalore campus 90 acres housing most of Syngene’s capabilities Discovery Services Hyderabad campus commenced operation in Aug 2019 API Manufacturing Mangalore campus Biologics Commissioned March 2020 Bangalore campus Capacity: 70KL Manufacturing plant scale: Rea
Slide 17: Experienced workforce: building capabilities and careers
Experienced workforce: building capabilities and careers ~6,000 Inspiring technical excellence and providing opportunities to grow total headcount Nurturing young • Syngene Training Academy offers new graduate recruits a six-month extended induction to help them 5000+ scientists talent and enhancing
Slide 18: Operational robustness driving strategy execution
Operational robustness driving strategy execution Continuous improvement embedded in operations Focused execution through strong Project driven by certified operational leaders Management Six Sigma Black Belt certified staff in each service line and Structured program management for executing client
Slide 19: Syngene strengths
3 Syngene strengths Syngene
Slide 20: Syngene strengths
Syngene strengths A global scale CRO/CDMO Solutions through innovation Quality matters • Integrated Drug Discovery, Development and • IP fully assigned to clients • Fully digitized quality organization Manufacturing service provider • Track record of data management and • Strong compliance track rec
Slide 21: Strong track record of growth and profitability
Strong track record of growth and profitability Total Revenue (Rs. Mn) EBITDA (Rs. Mn) Profit Before Tax * (Rs. Mn) FY18 to FY22 - CAGR 16% FY18 to FY22 - CAGR 13% FY18to FY18 toFY22 FY22--CAGR CAGR8% 8% 8,489 26,570 7,364 5,151 6,995 22,489 6,119 4,456 4,342 20,935 4,154 19,007 5,266 3,725 14,849 F
Slide 22: Levers for future growth
Levers for future growth Expand/extend existing clients Capacity expansion • Service integration • Continuous investment • Flexible business models including • FTE services, manufacturing, formulation, dedicated centers biologics, stability Engage New Clients • Tailored service offerings, high quali
Slide 23: Committed to safety and sustainability
Committed to safety and sustainability Safety is our first priority Committed to environmental protection • Accredited with ISO 45001:2018 for Occupational Health and Safety • Accredited with ISO 14001:2015 for our Environment Management System (OH&S) measures • 20% reduction in freshwater usage; 15
Slide 24: Industry recognition for our scientific capability and best practices
Industry recognition for our scientific capability and best practices • Bio-Excellence Award 2018: At Bengaluru • CMO Leadership Award Winner 2020 - under • CMO Leadership Awards 2022 Received 6 awards for all Tech Summit, Bengaluru Categories: Capabilities, Compatibility, categories, including Capa
Slide 25: Robust risk management framework
Robust risk management framework Syngene has a risk management framework to identify, monitor, report and manage risk Every risk owner monitors and manages risks relevant to their area of responsibility Executive Committee (EC) Board of Directors(BOD) • Sign-off on Enterprise Risk Framework annually
Slide 26: Financials
4 Financials
Slide 27: Q3FY23 financial highlights
Q3FY23 financial highlights Particulars Q3 FY23 Q3 FY22 YoY Change Q2 FY23 QoQ change Revenue from Operations 7,859 6,414 23% 7,681 2% Other income 172 129 34% 154 12% Total Revenue 8,031 6,543 23% 7,835 3% Material costs 2,061 1,721 20% 1,990 4% Staff costs 2,192 1,954 12% 2,185 0% Other direct cos
Slide 28: 9MFY23 financial highlights
9MFY23 financial highlights Particulars 9M FY23 9M FY22 YoY Change Revenue from Operations 21,985 18,461 19% Other income 481 381 26% Total Revenue 22,466 18,842 19% Material costs 5,664 5,342 6% Staff costs 6,347 5,611 13% Other direct costs 835 633 32% Other Expenses 2,561 1,872 37% Foreign exchan
Slide 29: FY22 financial highlights
FY22 financial highlights Particulars FY22 FY21 YoY Change Balance Sheet Highlights Revenue from operations (excl export incentives) 26,042 21,843 19% Other Income 528 646 (18%) Total Revenue 26,570 22,489 18% As on 31st March 2022 Material and power costs 8,138 5,839 39% Employee costs 7,181 6,602
Slide 30: Shareholding and Share Information
Shareholding and Share 5 Information
Slide 31: Syngene and Biocon Group
Syngene and Biocon Group Syngene is an operationally independent publicly listed Biocon Limited, founded in 1978, is an innovation-led global subsidiary of Biocon Limited, established in 1993 as India’s biopharmaceuticals company and has majority holding in key first Contract Research Organization.
Slide 32: Shareholding and Share Information
Shareholding and Share Information Syngene’s Shareholding Pattern* 0.5% Syngene’s Share Information* NSE Ticker SYNGENE Promoter & BSE Ticker 539268 34.6% Promoter Group Public Market Cap (Rs. Mn) 2,35,240 ESOP Trust % free-float 35% 64.9% Free-float market cap (Rs. Mn) 78,031 Share Outstanding (Mn)
Slide 33: For more details
For more details Visit our website www.syngeneintl.com https://twitter.com/SyngeneIntl https://www.linkedin.com/company/syngene-international-limited https://www.facebook.com/syngeneintl/ https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Krishnan G/ Suruchi Daga Sho
Slide 34: Appendix
J Appendix Syngene
Slide 35: Discovery Services
Discovery Services Target Identification and Hit HitHit to Lead to Lead Optimization Lead IND Enabling IND IND IND / Ph1 / DE Validation Identification Lead Optimization Enabling Ph1 DE Target ID In vitro assays: In In vitro vitro assays: assays: In Invivo vivoassays/studies: assays/studies: Later T
Slide 36: Development Services and Manufacturing Services
Development Services and Manufacturing Services Developability Development Clinical Phase Registration/process Commercial Assessment phase Phase I Phase II Phase III validation batches Early PK, MTD/DRF studies, • IND enabling GLP Tox studies: Ames, Chromosomal • NDA enabling studies: Sub- chronic a
Slide 37: Biologics Development and Manufacturing services
Biologics Development and Manufacturing services Developability Development Clinical Phase Registration/process Commercial Assessment phase Phase I Phase II Phase III validation batches • Cell line development / • Clone to GMP • Process DOE, robustness and safety study selection • Upstream process O
Slide 38: Thank you
Thank you © 2022 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the
Syngene International — Investor Presentation (December 2022) on 6ix